No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 612 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Scientists Focus on Fusion Proteins in Childhood Cancers August 4, 2020 Efficacy of a Bispecific Monoclonal Antibody Glofitamab for Relapsed or Refractory... December 19, 2022 Singer Surprises 6-Year-Old Fan Who Beat Cancer With Trip To Disney January 10, 2022 Camrelizumab Plus Rivoceranib Improves Survival Compared with Sorafenib in First-Line Treatment... August 2, 2023 Load more HOT NEWS Targeted prostate cancer screening: Are we there yet? Targeted drug recommended to treat some advanced lung cancer patients Cancer, COVID-19, and Competing Threats to Indigenous Health 2022 ASCO Annual Meeting: Social Services Spending and Cancer Survival, Clinical...
